Chapter 38: Parkinson’s Disease – Dopaminergic Drug Therapy

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today, we have a pretty vital mission for you.

Getting deep into the pharmacotherapy of Parkinson's disease.

That's right.

This is really essential knowledge for advanced practice students because, you know, you need to understand not just the drugs themselves, but the sort of high stakes clinical trade -offs involved in managing this really complex progressive neurodegenerative disorder.

Exactly.

And we're focusing squarely on chapter 38 today.

It confirms the main therapeutic goal isn't reversing PD.

Unfortunately, we just don't have agents for that yet, but it's about maintaining the patient's quality of life, really rigorously controlling both the motor and importantly, the non -motor symptoms.

Okay.

But before any treatment even starts, there's that critical first step you absolutely have to take.

Yes.

Absolutely critical.

You must rule out drug -induced Parkinsonism or DIP.

DIP.

So identifying if medications the patient is already on are actually mimicking the PD symptoms.

Precisely.

Which pharmaceutical offenders should practitioners be zeroing in on right away?

What are the common ones?

Well, the chapter highlights the usual suspects like first -generation antipsychotics.

No surprise there.

Okay.

But you also can't overlook things like metoclopramide, which is pretty common, or even valproic acid.

Right.

Identifying DIP is crucial because it's often reversible.

You just discontinue the offending agent.

If you miss that, well, you're treating the wrong condition entirely.

Okay.

So let's talk about the underlying problem we're trying to manage here.

We know PD is marked by the loss of those dopaminergic neurons in the substantia nigra pars compacta, right?

That's the one.

It leads to dopamine depletion in the corpus striatum.

And the sources mention that by the time motor symptoms actually become obvious, something like 60 to 80 % of those neurons might already be gone.

It's a significant loss, yeah.

That's why diagnosis can be tricky early on.

So with that much damage already done, when do we actually pull the trigger on starting treatment?

What dictates that timing?

The data highlighted in the chapter is pretty clear on this.

The strongest protectors that really push for immediate dopaminergic therapy are one, the severity of the symptoms, obviously.

Makes sense.

And two, often quite critically, the patient's employment status.

If symptoms interfere with daily function or especially their ability to work, therapy needs to begin, well, immediately.

Okay.

That's clear.

Let's then unpack the first group of drugs,

the mild potency agents.

These are often the first line in early PD, or sometimes for controlling specific symptoms, right?

Correct.

We often start here.

So we begin with the anticholinergics, like tri -hizphenidyl and benztropine.

Right.

Now, their use is a bit controversial, mainly due to side effects, but they do have a couple of strong indications.

Okay.

They're useful for managing severe drooling cialurea and they can be quite good for tremor.

Also, they're used for drug -induced extrapyramidal side effects, EPS.

And the mechanism.

How do they work?

They antagonize acetylcholine receptors.

This decreases acetylcholine release, which helps regulate muscle movement and can counterbalance the dopamine deficiency somewhat, especially for tremor.

Gotcha.

And there's a key clinical pearl here for you listening.

Sources really stress that you have to taper these agents when stopping them.

Absolutely.

You can't just stop them abruptly or you risk worsening side effects.

But like you hinted clinically, anticholinergics are often avoided, particularly in older patients.

Yeah.

Why is that?

Given they can be effective for tremor, why the reluctance?

It really just boils down to the cognitive burden.

These drugs have pretty significant central side effects, confusion, dry mouth, blurry vision, constipation, urinary retention.

The classic anticholinergic package.

Exactly.

And since older PD patients are already at a higher risk for cognitive decline or dementia, adding a medication that can worsen that confusion or memory is usually just not an acceptable trade off.

Plus the contraindication and narrow angle glaucoma.

Oh, absolutely.

That's a strict contraindication.

Can't use them there.

Okay.

Moving on then.

Let's talk amantadine.

This one can be used either as monotherapy early on or as an add on later.

Correct.

Its exact mechanism isn't perfectly understood, but it's thought to involve NMDA receptor inhibition and maybe potentiating the dopaminergic response that's still there.

What's interesting or maybe concerning are its specific side effects, which we'd be looking for.

Well, you get this sort of usual CNS suspects like hallucinations and confusion, which can be dose limiting.

But then you see some unique peripheral effects, ankle edema is one.

And then there's this very distinct skin condition called levido reticularis.

Yes, describe that for us.

What does it look like?

It looks like a sort of blotchy, purplish, net -like or fishnet pattern on the skin, usually on the legs.

It's vascular.

Seeing that is a pretty clear sign related to amantadine.

Good visual.

And for you advanced practice students, there's a really vital prescribing detail here regarding kidney function.

Yes, absolutely critical.

Amantadine is almost entirely cleared by the kidneys unchanged.

So the dosing must be adjusted based on creatinine clearance, the CRCL.

Can you give an example from the chapter?

Sure.

So for instance, if your patient's CRCL falls between 15 and 29 lmin, the maintenance dose has to be cut way back down to 100 mg, but only every other day.

And that's after a loading dose.

Wow, okay.

Yeah.

If you miss that calculation, you're basically guaranteeing toxicity because the drug will accumulate.

Very important dose adjustment.

Definitely noted.

Okay, let's shift gears to the MAOB inhibitors.

That's seligulin, risagulin and the newer one, cefinamide.

Right.

These offer, let's say, modest motor symptom improvement in early PD.

Their main benefit early on might be delaying the need for levodopa, maybe by a few months, though that's debated.

How do they achieve that, the MOA?

It's actually quite elegant.

They inhibit the enzyme monoamine oxidase type B.

MAOB is one of the key enzymes responsible for breaking down dopamine in the brain.

So less breakdown means?

More dopamine available at the synapse.

It boosts the existing dopamine levels.

They're generally pretty well tolerated compared to some other options, but they do come with important cautions.

Well, seligulin is metabolized into amphetamine metabolites.

Ah, right.

That can cause problems.

Yeah, particularly insomnia.

So you usually dose it earlier in the day.

Risagulin doesn't have that issue, which can be an advantage.

And what about interactions?

I remember the list being pretty significant for MAO inhibitors generally.

It is, and you have to be careful.

There are strict contraindications.

You absolutely avoid using them with moperidine or tramadol.

Okay.

And obviously you don't use them with other MAO inhibitors, A or B type.

There's also a significant risk of serotonin syndrome.

So using them with SSRIs, SNRIs or tricyclics requires real caution and monitoring.

What about the classic tiramine reaction, the cheese effect?

Good question.

With these selective MAOB inhibitors at their recommended doses, that risk is much, much lower than with the older non -selective MAOIs.

So strict diet isn't usually needed?

Generally, no.

The prescribing information usually mentions caution, but the very strict tiramine -free diet isn't typically required like it used to be.

Still, something to be aware of, especially if doses are pushed higher.

And saphenamide has a longer half -life, around 20 -26 hours, which might offer smoother coverage for some.

Okay, that's helpful.

Now, this is where the clinical picture, I think, gets really interesting.

Decision -making becomes key.

We're moving to the moderate -potency drugs.

The dopamine agonists, or DAs?

Yes, the DAs, PrimaPexil, Ropenarol, and the patchform, Rotogatine.

The challenge here seems to be balancing how well they work versus the side effects they bring, right?

Absolutely.

DAs work by directly stimulating the dopamine D2 -type receptors in the brain.

They kind of mimic dopamine.

But how do they stack up against levodopa, the gold standard?

Well, generally, they are less effective than levodopa for relieving motor symptoms.

That's the downside on efficacy.

But there must be an upside.

The crucial trade -off, and why we use them, is that they tend to cause those really debilitating motor fluctuations and dyskinesia much less frequently in the long run compared to levodopa.

Ah, so it's about the long game.

This sounds like a decision heavily based on the patient's age, then.

Exactly.

If you look at the treatment algorithms, like the one described in Figure 38 .2, DAs are typically the preferred initial therapy for younger patients.

Younger meaning?

Generally,

under about age 60, maybe 65, depending on the guideline and patient factors.

The rationale is that younger onset PD carries a significantly higher lifetime risk of developing severe dyskinesia from levodopa later on.

So you try to delay levodopa.

Okay, that makes sense strategy -wise.

And you mentioned different forms.

Yeah, we have flexibility.

Pramipexol and rapinarol come in immediate release, IR extended release, ER oral forms.

And rhodogatine is a transdermal patch applied once daily.

Any specific dosing adjustments to flag?

Yes, particularly for pramipexol, both IR and ER.

It needs dose reduction in patients with renal impairment, similar to amantadine but following its own schedule based on CRCL.

Rapinarol doesn't require renal adjustment, but might need care with hepatic impairment.

Got it.

And then there's epimorphine.

That's different, isn't it?

Very different.

Epimorphine is also a dopamine agonist, but it's an injectable formulation.

It's used strictly as a rescue therapy.

Rescue for what?

For acute intermittent off episodes, those times when the regular medications suddenly stop working and the patient becomes immobile or frozen.

This is usually seen in advanced PD.

It's not for routine daily use.

And because it's potent and injectable, I imagine initiating it isn't simple.

Not at all.

It requires a test dose, usually starting with 2 mg given subcutaneously, and it must be done under medical supervision like in a clinic.

Why supervised?

Because it can cause significant nausea, vomiting, and potentially severe hypotension.

So you monitor them closely.

If they tolerate the 2 mg but don't get a good motor response, you might try a 4 mg test dose a couple of hours later.

It's a very controlled initiation process.

Okay.

Let's circle back to the Hall DA class then.

We need to talk about the really critical adverse effects.

You mentioned fatigue, orthostatic hypotension, maybe some hallucinations.

Yes, those are common, especially orthostatic hypotension, which can cause falls.

Hallucinations are also more common with DAs than levodopa, especially in older folks.

But there are two really big ones, the ones that can cause genuine clinical crises.

Absolutely.

The two major concerns that often limit DAUs, particularly in older or cognitively vulnerable patients, are impulse control disorders, ICDs, and sudden unpredictable sleep attacks.

Let's break those down.

Impulse control disorders.

What does that actually mean in practice?

This is probably the most potentially devastating side effect from a psychosocial perspective.

We're talking about the allergens of new or worsening of existing compulsive behaviors, things like pathological gambling, hypersexuality, compulsive shopping or spending, binge eating.

Wow.

Yeah, it's not just a minor risk.

These behaviors can completely derail a patient's life, their finances, their family relationships.

It's catastrophic.

And it's directly linked to the stimulating reward pathways.

That requires serious counseling up front.

Mandatory.

You have to screen for risk factors and warn patients and families explicitly, and then the sleep attacks.

They are truly frightening.

How so?

Because they can happen literally without any warning.

A patient could be driving a car, eating a meal in the middle of a conversation, and suddenly just fall asleep.

While driving.

That's incredibly dangerous.

Yeah.

It's life -threatening.

This risk alone means you absolutely have to give strict counseling about driving safety, operating machinery.

For some patients, it means they simply cannot drive while on a DA.

This potential for severe cognitive and behavioral side effects is often the deciding factor to avoid DAs in older patients, even if it means accepting a higher long -term dyskinesia risk with Lovadopa.

That perfectly sets the stage for discussing the real cornerstone, the high -potency agent,

Lovadopa.

Almost always given combined with Carbidopa.

Yes.

The gold standard for symptomatic relief.

It's the most effective drug we have for the motor symptoms of PD, and it generally has the fastest onset of action.

So why Lovadopa and not just dopamine?

Ah, the fundamental issue.

Dopamine itself cannot cross the blood -brain barrier, the BBB.

Right.

Lovadopa, however, is a precursor molecule.

It can get transported across the BBB.

Once inside the brain, it gets converted into dopamine by an enzyme called dopadicarboxylase.

Okay, so Lovadopa gets in and becomes dopamine where needed.

What's Carbidopa's role, then?

Why is it always paired?

Carbidopa is the absolutely crucial co -star here.

That same enzyme, dopadicarboxylase, also exists in the periphery outside the brain.

Without Carbidopa, a large portion of the Lovadopa dose would get converted to dopamine in the bloodstream before reaching the brain.

Which would cause problems.

Big problems.

Lots of nausea and vomiting because dopamine receptors in the gut get stimulated, and unless Lovadopa actually making it to the brain to do its job, Carbidopa inhibits that peripheral decarboxylase enzyme.

So it protects the Lovadopa.

Exactly.

It allows much more Lovadopa to reach the brain.

The chapter suggests it increases central availability by roughly fourfold.

This means you can use a lower dose of Lovadopa overall, and it dramatically reduces those peripheral side effects, especially nausea.

You need at least 75 mg of Carbidopa per day to achieve effective peripheral blockade.

Okay, that combination makes sense.

Now you mentioned fascist onset, but Lovadopa has a notoriously short half -life.

It does, only about 60 to 90 minutes.

This is why patients need to take it multiple times a day, often starting at three times daily, but frequently increasing to four, five, even six times daily as the disease progresses.

And this short duration is what leads to the major long -term challenge.

The wearing off phenomenon.

Precisely.

Wearing off is when the drug's effect diminishes, and the motor symptoms tremor, rigidity, slowness start to return before the next scheduled dose is due.

The patient experiences increasing amounts of off -time during the day.

And this gets worse over time.

It does.

As the disease progresses and the brain loses more dopaminergic neurons, its ability to store and buffer the dopamine converted from Lovadopa decreases.

The response becomes much more dependent on the immediate plasma levels of Lovadopa, leading to those fluctuations.

And this is linked to dyskinesia too.

Yes.

Often, as patients require higher or more frequent doses to combat off -time, they start experiencing involuntary movements, wiggling, writhing, twisting called dyskinesia, usually when the Lovadopa levels peak.

It's a very difficult balancing act in advanced PD.

To try and manage this short window and maximize absorption, patient counseling on diet becomes really important, doesn't it?

Hugely important.

Especially regarding protein.

What's the issue with protein?

High protein intake, particularly large protein meals, can significantly reduce Lovadopa absorption from the gut.

The amino acids from the protein compete with Lovadopa for the same transport system across the intestinal wall and, importantly, also across the blood -brain barrier.

So less drug gets in.

Exactly.

Patients need to be advised to limit their protein portions, maybe to around 3 or 4 ounces per meal.

The chapter suggests visualizing the size of a bar of soap.

Practical tip.

Crucially, they should try to separate their Lovadopa doses from their meals, especially high protein meals, by maybe 30 minutes to an hour before or 1 to 2 hours after eating.

What about other dietary factors?

Constipation is a big one.

It's common in PD anyway, and it can significantly reduce and delay Lovadopa absorption.

Emphasizing high fluid intake and dietary fiber is really important not just for comfort, but for medication efficacy too.

When wearing off starts becoming a major problem, despite optimizing Lovadopa timing and diet, that's when we look at adding other agents.

Correct.

That's where the COMT inhibitors come in, Entacapone and Tolkapone.

COMT inhibitors.

These are purely adjunctive therapy.

Yes.

They're used only in combination with Lovadopa carbidopa, specifically to help manage wearing off.

They have no benefit on their own.

How do they work?

What's COMT?

COMT stands for catechol -O -metal -transferase.

It's another enzyme, primarily found in the periphery, that breaks down Lovadopa.

So, similar to carbidopa's target, but a different enzyme.

Exactly.

By inhibiting COMT, these drugs block this other pathway of peripheral Lovadopa breakdown.

This increases the plasma levels of Lovadopa and, importantly, prolongs its half -life.

So the Lovadopa dose lasts longer.

Effectively, yes.

It helps smooth out those end -of -dose wearing off periods and can increase the daily on -time for the patient.

Okay, but there's a huge safety difference between the two, right?

Tolkapone has that black box warning.

It does.

A major one.

Tolkapone carries a black box warning for potentially fatal hepatotoxicity liver damage.

Wow.

Well, Entacapone does not have this warning.

Correct.

Entacapone does not carry that same liver risk.

Clinically, this makes a massive difference.

So, is there any reason these days to actually choose Tolkapone, given that liability?

Or is Entacapone just the go -to COMT inhibitor?

Entacapone is absolutely the preferred and overwhelmingly more commonly used agent, precisely because it avoids that specific hepatic risk.

Tolkapone requires extremely strict liver function test monitoring LFTs every two to four weeks for the first six months and then periodically thereafter.

That's a huge burden.

It is.

While both drugs can sometimes worsen Lovadopa side effects like dyskinesia, sometimes requiring a Lovadopa dose reduction.

And both can cause diarrhea and harmless dark orange or brownish discoloration of the urine.

Right.

Need to warn patients about the urine color change.

Definitely.

But the monitoring requirements and the sheer risk associated with Tolkapone mean it's very rarely used today.

It's usually reserved only for patients who have failed or cannot tolerate Entacapone and have significant wearing off.

Entacapone is the standard choice.

Okay.

That clarifies the COMT inhibitors.

Let's try and tie this all together now.

We've discussed the different drug classes.

Yeah.

How does an advanced practice student actually apply this?

How do you approach selecting the initial drug based on the patient in front of you?

Right.

This is where we need to sort of verbalize that treatment algorithm, like the one in figure 38 .2.

It depends heavily on symptom severity and patient age cognitive status.

Okay.

Walk us through it.

Mild symptoms first.

So for a patient presenting with functionally mild motor symptoms, maybe some tremor or stiffness, but not really impacting their daily life significantly, the options are typically an MAOB inhibitor, amantadine, or maybe an anticholinergic.

But we said anticholinergics are generally avoided.

Generally, yes, especially in older adults due to the cognitive risks we talked about.

So the choice often comes down to amantadine versus an MAOB inhibitor.

How do you choose between those two?

Amantadine might be favored in a younger patient whose main issues are tremor or perhaps fatigue.

MAOB inhibitors might be preferred in older patients or those with renal dysfunction, where amantadine dosing is tricky, assuming they can tolerate the potential drug interactions and side effects.

Okay.

That covers mild.

What about when symptoms are more moderate to severe when they're impairing function?

Then the initial choice really boils down to starting either a dopamine agonist, DA, or livadopa carbidopa.

And here's that age rule again.

Exactly.

We strongly reinforce the age consideration.

For the younger patient, typically under 60 or 65, the guideline generally favors starting with a DA.

Why again?

Remind us.

To delay the introduction of livadopa and hopefully postpone or reduce the long -term risk of developing those motor fluctuations and disabling dyskinesia.

Okay.

And for the older patient?

For older patients, say over 65 or 70, or for any patient regardless of age who already has significant cognitive impairment or psychosis risk, livadopa is generally the preferred initial agent.

Why livadopa in that group?

Because it has superior motor symptom efficacy.

And crucially, it has a lower risk of inducing those problematic cognitive side effects like hallucinations and psychosis compared to the DAs.

In a frail or cognitively vulnerable patient, the risks of DA side effects often outweigh the potential long -term benefit of avoiding dyskinesia.

Livadopa is usually better tolerated from a neuropsychiatric standpoint.

That's a really clear decision pathway.

Now we can't finish without touching on the non -motor symptoms.

These often have an even bigger impact on quality of life than the motor ones.

Absolutely.

Managing these is critical.

Psychosis is unfortunately quite common in later PD.

What are the go -to treatments there?

Clozapine and quesapine have the best evidence.

However, quesapine is generally preferred first line.

Why quesapine over clozapine?

Because clozapine requires that intensive blood monitoring due to the risk of a granulocytosis, the severe drop in white blood cells.

It's effective, but the monitoring is burdensome.

Quesapine doesn't require that.

Importantly, which antipsychotics should be avoided in PD patients?

This is crucial.

You must actively avoid typical antipsychotics and even some atypicals like olanzapine, risperidone, and aripiprazole.

They are known to worsen motor symptoms in PD patients significantly because they block D2 receptors more strongly.

Very important point.

What about the cognitive decline and dementia that often develops?

For that, the cholinesterase inhibitors ribostigmine and dunimpeasal have shown benefit and are commonly used, similar to their use in Alzheimer's disease.

Ribostigmine has a specific indication for PD dementia.

Okay, and one last common one.

Orthostatic hypotension.

That dizziness on standing.

Yeah, a frequent cause of falls.

Non -drug measures first, of course, like hydration, salt intake, compression stockings.

But pharmacologically, options include flutricortisone, midadrine, and droxodopa.

Droxodopa seems to have more short -term efficacy based on studies.

Got it.

Wow, this has been an incredibly dense tour through PD pharmacotherapy.

To wrap up, the core dilemma you'll face in practice seems to be this constant balancing act.

It really is.

PD treatment is intensely individualized.

It's stepwise, symptom -focused, and based on calculated risk assessment for each specific patient.

Levodopa gives the best bang for the buck symptomatically.

Right.

It's the most potent.

But its long -term use almost inevitably leads to those challenging motor complications like wearing off and dyskinesia.

Whereas the DAs offer a lower risk of dyskinesia long -term.

But they trade away some of that efficacy, and more importantly, they introduce those much more acute and often catastrophic risks of severe cognitive and behavioral side effects, those life -altering ICDs and the sudden sleep attacks we discussed.

Mastering that specific trade -off for each patient is really the art of PD management.

So even with this impressive arsenal of symptomatic treatments, we're still fundamentally just managing symptoms.

We aren't stopping the disease itself.

That's the hard truth right now.

The sources confirm that despite all these options, we still lack any truly disease -modifying or neuroprotective agents that can slow or halt the underlying progression of neurodegeneration.

But is there hope on the horizon?

What does the future look like?

Well, the chapter does mention that research is accelerating rapidly.

There's a lot of focus on understanding the genetics of PD, looking into things like alpha -synuclein, and exploring novel therapeutic approaches, like maybe using viral vectors to deliver genes that could silence PD -related processes, or perhaps even promote neuron survival.

So moving beyond just replacing dopamine.

Exactly.

The hope is that the future of PD treatment might finally shift from purely managing symptoms to actually intervening in the disease process itself.

We're not there yet, but the research is pushing hard in that direction.

That is a powerful and hopeful thought to leave you all with.

Thank you so much for joining us on this really essential deep dive into Parkinson's disease pharmacotherapy.

Yes, thank you.

We hope this helps you translate this complex information into your clinical practice.

And thanks, as always, for being part of our little last -minute lecture family.